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Introduction 
Across the United States, children diagnosed with acute lymphoblastic leukemia (ALL) following 
Children’s Oncology Group (COG) protocols undergo standard 3 or 4-drug induction chemotherapy. 
However, length of stay (LOS) and antibiotic practices during induction chemotherapy vary by 
institution. Much less is known about hospital practices and outcomes during induction chemotherapy 
from small institutions similar to ours. At our institution, there are on average 30 to 35 newly diagnosed 
oncology patients every year. Previously, our hospital practice included keeping high risk patients 
undergoing 4-drug induction chemotherapy longer in the hospital through absolute neutrophil count 
(ANC) nadir prior to discharge home. According to Wedekind et al,1 long LOS hospitals had lower 
odds of any readmission. Of note, such odds were higher in patients >10 years or girls, with the top 
2 most common diagnoses at readmission being neutropenia and fever.1 Literature suggests that 
infectious complications occur in 20-35% of patients undergoing induction chemotherapy. Slone et 
al2 found 39% of patients had infectious complications during induction chemotherapy with a 25% 
readmission rate. According to Sulis et al,3 reported bacterial infections during induction chemotherapy 
accounted for 25% of patients. Other factors such as young age, white race, intensive chemotherapy, 
and lack of neutrophil surge after dexamethasone treatment was associated with infection-related 
complications.4 After several infectious complications in one year at our institution, the purpose of 
this retrospective review was to evaluate the influence of our hospital practices in relation to 
morbidity during induction chemotherapy within the last decade of care. 
Methods
•  Retrospective chart review
•  Inclusion criteria: Patients 1 to 21 years of age 
with newly diagnosed ALL or lymphoblastic 
lymphoma (LLy) at our institution between 
May 1, 2020 and May 31, 2020
•  Exclusion criteria: infant ALL, acute myeloid 
leukemia (AML), and Down’s Syndrome
•  Eligible patients had to complete entirety of 
induction chemotherapy at our institution
•  Infectious complications during initial 
hospitalization were defined as documented 
bacterial infection during hospital stay prior  
to discharge. This included positive 
microbiological culture, sepsis, clinical 
findings of abscess or cellulitis, and/or 
radiological evidence of deep soft  
tissue infection. 
•  Readmission infectious complication was 
defined as documented bacterial infection  
or fever on readmission. 
•  Length of stay (LOS) categorized as the 
following, taking into account for patients  
with weekend admissions and time to 
chemotherapy initiation:
  Short LOS ≤11 days
  Medium LOS 12-15 days 
  Long LOS ≥16 d
•  Fever was defined as at least one oral 
temperature of 38.3°C or two consecutive 
temperatures  
of 38°C in 1 hour.
•  Readmission period included the first 30 
days following the initial day of admission for 
diagnosis and induction chemotherapy. 
Statistical Analysis 
The primary outcome was to evaluate infectious complications and readmission rates during 
induction chemotherapy. Two patient groups were compared in regard to LOS, type of induction, 
age, sex, comorbidities, risk stratification, and central line type utilizing t-test, where appropriate. 
Two-sided tests of significance were utilized and a P< 0.05 were specified as statistically 
significant. A multivariate analysis has not been performed yet.
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Of the 72 patients, 14 (19%) had infectious complications during the entirety of induction chemotherapy 
(Table II). Only 9 (13%) patients were readmitted for infectious complications or fever. The most 
common infectious complication during induction chemotherapy included bacteremia and neutropenic 
fever (Table II). The most common organism found on readmission was methicillin-susceptible 
Staphylococcus aureus (MSSA) bacteremia (56%). Patients undergoing 3-drug induction had 
increased rates of infectious complications during induction chemotherapy as compared to those 
undergoing 4-drug induction (Table III). 
Table IV: Length of stay and readmission rate for infectious complications 
between those patients undergoing 3-drug verse 4-drug induction 
chemotherapy protocols
Short LOSa  
(%) (range)
Medium LOSb  
(%) (range)
Long LOSc  
(%) (range)
Induction protocol
3-drug induction (N=40) 22 (55%) (6-11d) 8 (20%) (12-14d) 10 (25%) (15-30d)
4-drug induction (N=32) 5 (16%) (6-10d) 1 (13%) (13d) 26 (81%) (16-33d)
P-value 0.0007 0.429 <0.00001
Readmission rate
3-drug induction (N=40) 1 (5%) 2 (25%) 2 (20%)
4-drug induction (N=32) 3 (60%) 0 1 (4%)
P-value 0.002 0.569 0.121
LOS, length of stay; aShortLOSdefinedas≤11days;bMediumLOSdefinedas12-15days;cLongLOSdefinedas≥16days.
Table V: Readmission rate for infectious complications evaluated by age
N (%) P-value
Readmission rate
Age <10 years 7 (78%) 0.017
Age ≥10 years 2 (22%)
Conclusion
We found lower (19%) but comparable total rate of infectious complications during ALL 
induction chemotherapy as reported in the literature.2,3 However, our rate of readmission (13%) 
as well as rates of infectious complications or fever when readmitted, was much lower. 
Furthermore, when stratified by NCI risk group or 3-drug vs. 4-drug induction, we did not see 
a difference. Similarly, to Inaba et al,4 we found that young age (<10 years) was associated with 
increased rate of infectious complications on readmission during induction (78%). Limits of the 
study include the retrospective nature of the review as well as the lack of a robust statistical 
analysis that accounted for a variety of factors including multivariate analysis. Our study 
demonstrated that patients undergoing 4-drug induction chemotherapy who had a short LOS 
(≤11 days) had increased rates of readmission and infectious complications. On the contrary, 
patients undergoing 3-drug induction chemotherapy with short LOS had lower rates of 
readmission for infectious complications. We believe the practice of keeping SR patients until at 
least day 8 of induction and most of those receiving 4-drug induction past absolute neutrophil 
count nadir or LOS ≥16 days, may account for our favorable findings. Now, with literature 
supporting levofloxacin prophylaxis during induction chemotherapy for prevention of febrile 
neutropenia and systemic infection5, earlier discharge for high-risk patients is a consideration. 
Table I: Demographic characteristics 
of the 72 patients during induction 
chemotherapy   
N (%) P-value
Age
1-10 years 53 (74%)
>10 years 19 (26%) <0.00001
Sex
Female 30 (42%)
Male 42 (58%) 0.0549
Race
White 52 (72%)









Yes 68 (94%) 
No 4 (6%) <0.00001
Central line type
PICC 44 (61%)





ALL risk stratification 
High risk B-ALL 22 (31%)
Standard risk B-ALL 38 (53%) 0.0076
Chemotherapy protocol
3-drug induction 40 (56%)
4-drug induction 32 (44%) 0.1499
PICC, peripherally inserted central catheter; B-ALL, B-cell acute lymphoblastic 
leukemia; T-ALL, T-cell acute lymphoblastic leukemia; T-LLy, T-cell lymphoblastic 
lymphoma. 
Table II: Infectious complication 
characteristics during induction 
chemotherapy 
N (%)
Total Infectious Complications 14 (19%)
Bacteremia
Methicillin-susceptible 
Staphylococcus aureusa 5 (36%)
Escherichia colib 1 (7%)
Pseudomonas 1 (7%)
Group B streptococcus 1 (7%)
Streptococcus pneumoniae 1 (7%)
Moraxella 1 (7%)
Sepsis, blood culture negative 1 (7%)
C. difficile infection 1 (7%)
Neutropenic fever 5 (36%)





a On readmission, Methicillin-susceptible Staphylococcus aureus bacteremia 
was the predominate organism found at 56%
b Escherichia coli bacteremia was the second most common organism at 11%; 
MRSA, Methicillin-resistant Staphylococcus aureus was not found. No deaths 
wereidentified.
Table III: Infectious complications during 
induction chemotherapy between those 
undergoing 3-drug verse 4-drug 
induction chemotherapy protocols 
Chemotherapy protocol N (%)
3-drug induction 9 (64%)
4-drug induction 5 (36%)
There were significant differences in LOS. Twenty-two of the 40 patients (55%) who received 3-drug 
induction had short LOS (≤11 d) as compared to 5 (16%) of the 32 patients with 4-drug induction 
(P=0.0007). Contrary, 26 (81%) of these patients had long LOS (≥16 d) as compared to 10 (25%) of 
patients who received 3-drug induction (P=<0.00001). Both of these findings were statistically 
significant (Table IV). Most of the few patients undergoing 4-drug induction chemotherapy with short 
LOS were readmitted with infectious complications (60%). This was also statistically significant.  
Interestingly, most of the readmitted patients were <10 years of age (Table V). 
